Weighted Average Number of Shares Outstanding, Diluted of eFFECTOR Therapeutics, Inc. from 30 Jun 2020 to 31 Mar 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
eFFECTOR Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 30 Jun 2020 to 31 Mar 2024.
  • eFFECTOR Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 31 Mar 2024 was 4,081,580, a 143% increase year-over-year.
  • eFFECTOR Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 2,186,954, a 33% increase from 2022.
  • eFFECTOR Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 1,647,183, a 95% decline from 2021.
  • eFFECTOR Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 36,004,063, a 1256% increase from 2020.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

eFFECTOR Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 4,081,580 +2,401,548 +143% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 2,186,954 +539,771 +33% 01 Oct 2023 31 Dec 2023 10-K 26 Mar 2024 2023 Q4
Q3 2023 61,767,952 +20,595,962 +50% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2023 2023 Q3
Q2 2023 47,828,631 +6,709,904 +16% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 1,680,032 -41,702,412 -96% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 1,647,183 -34,356,880 -95% 01 Oct 2022 31 Dec 2022 10-K 26 Mar 2024 2023 Q4
Q3 2022 41,171,990 +21,104,275 +105% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 41,118,727 +39,668,568 +2735% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 43,382,444 +41,937,379 +2902% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 36,004,063 01 Oct 2021 31 Dec 2021 10-K 08 Mar 2023 2022 Q4
Q3 2021 20,067,715 +18,629,131 +1295% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 1,450,159 -27,106,508 -95% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 1,445,065 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q3 2020 1,438,584 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 28,556,667 01 Apr 2020 30 Jun 2020 8-K 31 Aug 2021

eFFECTOR Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 2,186,954 +539,771 +33% 01 Jan 2023 31 Dec 2023 10-K 26 Mar 2024 2023 FY
2022 1,647,183 -34,356,880 -95% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
2021 36,004,063 +33,349,214 +1256% 01 Jan 2021 31 Dec 2021 10-K 08 Mar 2023 2022 FY
2020 2,654,849 01 Jan 2020 31 Dec 2020 10-K 16 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.